skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PharmaLogo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?


Download Potential of First-in-Class Epidiolex for Epilepsy and its Significance in the Advent of Medical Marijuana and Discover:

  • Epidiolex's potential as a first-in-class drug in the epilepsy market and the first FDA-approved drug for Dravet syndrome
  • Regulatory repercussions in the form of drug scheduling following the first cannabis plant-derived drug to receive FDA approval
  • Biomedtracker analyses, including change to Likelihood of Approval (LOA)
  • In-depth analysis of historical trends and the current global status of cannabinoid drug development for targeted indications
  • Evaluation of important issues pertinent to medicinal cannabinoid development and its potential to successfully address the opioid crisis
    •
Download whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now